[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657593":3},{"organization":4,"outcomesModule":7,"designInfo":59,"detailedDescription":68,"studyPopulation":64,"armGroups":69,"interventions":82,"overallOfficials":64,"centralContacts":64,"locations":64,"responsibleParty":93,"collaborators":95,"id":101,"slug":102,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":64,"studyType":115,"phases":116,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":132,"whyStopped":64,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":64},{"fullName":5,"class":6},"Xiangya Hospital of Central South University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":54},[9],{"measure":10,"description":11,"timeFrame":12},"Change in Carotid Plaque Area","The change from baseline in the maximum cross-sectional area of carotid atherosclerotic plaques measured by carotid ultrasound at 6 months after initiation of treatment. Plaque area is quantified as the difference between baseline and 6-month measurements, with a negative value indicating reduction in plaque area.","Baseline and 6 months after treatment initiation",[14,18,21,24,27,30,33,36,39,42,45,48,51],{"measure":15,"description":16,"timeFrame":17},"Change in Serum Lipid Profile","Change from baseline in serum levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol measured at 3 months and 6 months after treatment initiation.","Baseline, 3 months, and 6 months",{"measure":19,"description":20,"timeFrame":17},"Change in CD4+ T-Cell Proportion Among PBMCs","Change from baseline in the proportion of CD3+CD4+ T cells among viable peripheral blood mononuclear cells, measured by multiparameter flow cytometry and reported as a percentage (%).",{"measure":22,"description":23,"timeFrame":17},"Change in Inflammatory Cytokine Levels","Change from baseline in serum levels of inflammatory cytokines (including interleukin-6, tumor necrosis factor-alpha, and interleukin-1β) measured at 3 months and 6 months after treatment initiation.",{"measure":25,"description":26,"timeFrame":17},"Change in Gut Microbiota Shannon Diversity Index","Change from baseline in within-sample bacterial alpha diversity measured by 16S rRNA gene sequencing and reported as the unitless Shannon diversity index.",{"measure":28,"description":29,"timeFrame":17},"Change in CD8+ T-Cell Proportion Among PBMCs","Change from baseline in the proportion of CD3+CD8+ T cells among viable peripheral blood mononuclear cells, measured by multiparameter flow cytometry and reported as a percentage (%).",{"measure":31,"description":32,"timeFrame":17},"Change in CD19+ B-Cell Proportion Among PBMCs","Change from baseline in the proportion of CD3-CD19+ B cells among viable peripheral blood mononuclear cells, measured by multiparameter flow cytometry and reported as a percentage (%).",{"measure":34,"description":35,"timeFrame":17},"Change in Natural Killer Cell Proportion Among PBMCs","Change from baseline in the proportion of CD3-CD56+ natural killer cells among viable peripheral blood mononuclear cells, measured by multiparameter flow cytometry and reported as a percentage (%).",{"measure":37,"description":38,"timeFrame":17},"Change in CD4+\u002FCD8+ T-Cell Ratio","Change from baseline in the unitless ratio of CD3+CD4+ T-cell proportion to CD3+CD8+ T-cell proportion among viable peripheral blood mononuclear cells, measured by multiparameter flow cytometry.",{"measure":40,"description":41,"timeFrame":17},"Change in Gut Microbiota Chao1 Richness Index","Change from baseline in estimated bacterial taxon richness measured by 16S rRNA gene sequencing and reported as the unitless Chao1 richness index.",{"measure":43,"description":44,"timeFrame":17},"Change in Relative Abundance of Prespecified Gut Bacterial Taxa","Change from baseline in the relative abundance of each prespecified bacterial taxon measured by 16S rRNA gene sequencing and reported as the percentage of quality-filtered sequencing reads assigned to the taxon (%).",{"measure":46,"description":47,"timeFrame":17},"Change in Fecal Acetate Concentration","Change from baseline in fecal acetate concentration measured by a validated gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) assay and reported as micromoles per gram of wet stool (µmol\u002Fg).",{"measure":49,"description":50,"timeFrame":17},"Change in Fecal Propionate Concentration","Change from baseline in fecal propionate concentration measured by a validated gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) assay and reported as micromoles per gram of wet stool (µmol\u002Fg).",{"measure":52,"description":53,"timeFrame":17},"Change in Fecal Butyrate Concentration","Change from baseline in fecal butyrate concentration measured by a validated gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-mass spectrometry (LC-MS) assay and reported as micromoles per gram of wet stool (µmol\u002Fg).",[55],{"measure":56,"description":57,"timeFrame":58},"Incidence of Adverse Events","Proportion of participants experiencing treatment-emergent adverse events, assessed by clinical evaluation and laboratory tests throughout the study period and up to 28 days after the last dose of Rosa roxburghii freeze-dried powder.","From enrollment through 28 days after last dose (up to approximately 7 months)",{"allocation":60,"interventionModel":61,"interventionModelDescription":62,"primaryPurpose":63,"observationalModel":64,"timePerspective":64,"maskingInfo":65},"RANDOMIZED","PARALLEL","This study employs a parallel-group design with two arms: an experimental group receiving conventional anti-atherosclerosis therapy plus Rosa roxburghii freeze-dried powder, and an active comparator group receiving conventional therapy alone. Participants are randomized in a 1:1 allocation ratio. The treatment period lasts 6 months, followed by a 2-month safety follow-up period. No crossover or factorial design is applied. The parallel assignment allows for direct comparison of the intervention effect between the two independent groups while minimizing carryover effects.","TREATMENT",null,{"masking":66,"maskingDescription":67,"whoMasked":64},"NONE","This is an open-label study. No masking is applied, as participants, investigators, and outcome assessors are aware of the assigned interventions. The open-label design is due to the nature of the intervention (oral administration of Rosa roxburghii freeze-dried powder) and the absence of a placebo control. To minimize potential bias, objective outcome measures (e.g., ultrasound assessment of plaque size, laboratory parameters) are used, and outcome assessors will be independent and blinded to group assignment during data analysis where feasible.","Atherosclerosis, particularly carotid artery plaque, is a critical risk factor for acute ischemic stroke. Current pharmacological interventions, such as statins, are effective but have safety concerns that limit long-term use. Rosa roxburghii Tratt, a food-medicine homology plant, possesses antioxidant, anti-inflammatory, and lipid-regulating properties. Preclinical studies suggest that its active components may modulate lipid metabolism and inflammation, potentially through gut microbiota-mediated pathways.\n\nThis study is a multicenter, randomized, parallel-controlled, real-world clinical trial designed to investigate the efficacy and safety of Rosa roxburghii freeze-dried powder in patients with carotid atherosclerotic plaques. A total of 200 participants meeting the inclusion criteria will be enrolled and randomly assigned in a 1:1 ratio to either the experimental group (conventional anti-atherosclerosis therapy plus Rosa roxburghii freeze-dried powder 3 g\u002Fday orally for 6 months) or the control group (conventional therapy alone). Conventional therapy includes statins and antiplatelet agents prescribed according to standard clinical practice.\n\nThe study consists of a screening period, a 6-month treatment period, and a 2-month follow-up period. Clinical assessments are scheduled at baseline, 3 months, and 6 months. The primary outcome measures are the change from baseline in carotid plaque area assessed by ultrasound and serum lipid levels (total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) at 6 months. Secondary outcome measures include changes in peripheral blood mononuclear cell characteristics and gut microbiota composition with metabolomic profiles. Safety outcomes include the incidence of adverse events and serious adverse events.\n\nBiological samples (fasting blood and feces) are collected at baseline, 3 months, and 6 months for mechanistic studies. Blood samples will be used for peripheral blood mononuclear cell isolation and biomarker analysis. Fecal samples will undergo 16S rRNA sequencing and untargeted metabolomics to explore the gut microbiota-metabolite axis underlying the intervention effects. The sample size calculation assumed a 90% power and a 30% attrition rate, yielding 100 participants per group. Statistical analyses will include descriptive statistics, correlation analyses for efficacy, and safety evaluations using CTCAE criteria. This study is expected to provide robust clinical evidence on the efficacy and mechanism of Rosa roxburghii as an adjunctive therapy for carotid atherosclerosis, potentially offering a safe and accessible option for stroke prevention.",[70,77],{"label":71,"type":72,"description":73,"interventionNames":74},"Rosa Roxburghii Freeze-Dried Powder Plus Conventional Therapy","EXPERIMENTAL","Participants receive conventional anti-atherosclerosis therapy (including statins, antiplatelet agents such as aspirin, as prescribed by the attending physician) plus Rosa roxburghii freeze-dried powder administered orally at a dose of 3 g once daily after lunch for 6 months.",[75,76],"Dietary Supplement: Rosa Roxburghii Freeze-Dried Powder","Drug: Conventional Anti-Atherosclerosis Therapy",{"label":78,"type":79,"description":80,"interventionNames":81},"Conventional Therapy Alone","ACTIVE_COMPARATOR","Participants receive conventional anti-atherosclerosis therapy (including statins, antiplatelet agents such as aspirin, as prescribed by the attending physician) without Rosa roxburghii supplementation. Treatment follows standard clinical practice.",[76],[83,88],{"type":84,"name":85,"description":86,"armGroupLabels":87,"otherNames":64},"DIETARY_SUPPLEMENT","Rosa Roxburghii Freeze-Dried Powder","Rosa roxburghii freeze-dried powder (3 g per sachet) administered orally at a dose of 3 g once daily after lunch for 6 months.",[71],{"type":89,"name":90,"description":91,"armGroupLabels":92,"otherNames":64},"DRUG","Conventional Anti-Atherosclerosis Therapy","Standard-of-care treatment for atherosclerosis including statins (e.g., atorvastatin, rosuvastatin) and antiplatelet agents (e.g., aspirin) as prescribed by the attending physician according to clinical practice guidelines. Dosing and duration follow routine clinical management.",[78,71],{"type":94,"investigatorFullName":64,"investigatorTitle":64,"investigatorAffiliation":64,"oldNameTitle":64,"oldOrganization":64},"SPONSOR",[96,98],{"name":97,"class":6},"The First People's Hospital of Guiyang",{"name":99,"class":100},"Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd.","UNKNOWN","100657593","effects-of-rosa-roxburghii-tratt-freeze-dried-powder-on-carotid-atherosclerotic-plaques-a-real-world-study-100657593",false,"NCT07840950","Effects of Rosa Roxburghii Tratt Freeze-Dried Powder on Carotid Atherosclerotic Plaques: A Real-World Study","Mechanism of Action and Real-World Study of Rosa Roxburghii Tratt Freeze-Dried Juice Powder and Its Extracts Against Carotid Atherosclerotic Plaques","RRC-AS","Inclusion Criteria:\n\n* Participants clinically diagnosed with atherosclerosis (AS) by a specialist physician\n* Age between 40 and 80 years\n* Presence of at least one identifiable carotid plaque meeting all of the following criteria: (a) a focal structure protruding into the lumen; (b) on gray-scale ultrasound longitudinal\u002Ftransverse sections, protrusion beyond the vascular intimal surface with a maximum thickness ≥ 1.5 mm compared with the adjacent normal vessel wall (1-2 cm proximal or distal to the plaque); (c) a local structure protruding into the lumen with a thickness ≥ 0.5 mm or \\> 50% of the surrounding intima-media thickness (IMT), accompanied by abnormal lipid metabolism markers\n* Diagnosis of carotid plaque and regular follow-up with the same physician at the study site\n* Willingness to refrain from participating in other clinical studies and to complete the full treatment regimen during the study period\n* Voluntarily sign the informed consent form after being fully informed\n\nExclusion Criteria:\n\n* History of allergy to Rosa roxburghii juice or vitamin C preparations\n* Hyperlipidemia without detectable carotid plaques\n* Severe malnutrition\n* Concomitant liver or kidney disease\n* Pregnancy or lactation\n* Psychiatric disorders or inability to cooperate with the study procedures\n* Diagnosis of diabetes mellitus or hypertension\n* Use of antibiotics, probiotics, prebiotics, laxatives, or traditional Chinese medicine within 3 months prior to enrollment\n* Any condition that, in the investigator's opinion, makes the participant unsuitable for enrollment","ALL","40 Years","80 Years",{"count":113,"type":114},200,"ESTIMATED","INTERVENTIONAL",[117],"NA","This study aims to evaluate the effectiveness and safety of Rosa roxburghii freeze-dried powder in reducing carotid atherosclerotic plaques. Carotid atherosclerosis is a major cause of ischemic stroke, and current treatments have safety limitations. Rosa roxburghii, a fruit used in traditional Chinese medicine, has shown potential in lowering lipids and reducing inflammation. In this randomized controlled trial, 200 participants with carotid plaques will be assigned to either conventional therapy alone or conventional therapy plus Rosa roxburghii freeze-dried powder (3 g\u002Fday for 6 months). The primary outcomes are changes in plaque size assessed by ultrasound and serum lipid levels. Secondary and exploratory outcomes include changes in inflammatory markers, gut microbiota composition, and metabolomic profiles. The study will provide clinical evidence on the use of Rosa roxburghii as an adjunctive therapy for atherosclerosis.",[120,121,122],"Carotid Artery Plaques","Atherosclerosis","Ischemic Stroke",[124,125,126,127,128,129,130,131],"Rosa roxburghii","Carotid atherosclerosis","Plaque regression","Lipid metabolism","Gut microbiota","Real-world study","Traditional Chinese medicine","Food-medicine homology","NOT_YET_RECRUITING","2026-09-19",{"date":135,"type":136},"2026-09-25","ACTUAL",{"date":138,"type":114},"2026-09-01",{"date":140,"type":114},"2029-01-31",{"name":5,"class":6}]